Comprehensive medication guide to {drug} including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Dexmethylphenidate XR is an extended-release CNS stimulant prescribed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. It is the purified, pharmacologically active d-threo enantiomer of racemic methylphenidate, which means it contains only the more potent half of the methylphenidate molecule. The brand-name version is sold as Focalin XR, manufactured by Novartis Pharmaceuticals.
The extended-release formulation provides symptom control throughout the day with a single morning dose, typically lasting 8 to 12 hours. Adults typically start at 10 mg per day and may increase up to 40 mg per day, while children start at 5 mg per day with a maximum of 30 mg per day.
Dexmethylphenidate XR works as a norepinephrine-dopamine reuptake inhibitor (NDRI). It blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing the availability of these neurotransmitters in the synaptic cleft. This enhanced neurotransmitter activity in the brain's prefrontal cortex helps improve attention, focus, and impulse control in people with ADHD.
The extended-release capsule uses a bi-modal release system — half the dose releases immediately and the other half releases approximately four hours later — providing consistent symptom coverage throughout the day without the need for a second dose.
Dexmethylphenidate XR capsules are taken once daily in the morning. The capsules can be swallowed whole or opened and sprinkled on applesauce for patients who have difficulty swallowing.
Dexmethylphenidate XR has a findability score of 40 out of 100, meaning it is frequently difficult to find in stock. As of early 2026, Dexmethylphenidate XR remains on the FDA's active drug shortage list. Multiple manufacturers have various strengths on back order with no estimated release dates. The broader ADHD stimulant shortage that began in October 2022 continues to affect supply. DEA production quota limitations, increased demand, and manufacturing delays have all contributed to ongoing supply disruptions.
If your local pharmacy is out of stock, try using Medfinder to search nearby pharmacies that may have your dose available. Calling independent pharmacies rather than large chains can also improve your chances of finding it.
Struggling to find {drug} in stock? We'll call the pharmacies, sit on hold, and find you one that can fill your prescription.
Because Dexmethylphenidate XR is a Schedule II controlled substance, it requires a prescription from a licensed prescriber with DEA authorization. The following types of doctors and providers commonly prescribe it:
Telehealth providers can also prescribe Dexmethylphenidate XR in many states, though regulations for controlled substance prescribing via telemedicine vary by state.
Yes, Dexmethylphenidate XR is classified as a Schedule II controlled substance by the DEA. This is the most restrictive category for drugs with accepted medical use, indicating a high potential for abuse and dependence.
As a Schedule II substance, prescriptions for Dexmethylphenidate XR cannot be called in to pharmacies — they must be written or sent electronically. Refills are not permitted; a new prescription is required each time. Most states limit prescriptions to a 30-day supply, though some allow up to 90 days. These restrictions can make it more challenging to obtain, especially during shortages.
Serious side effects can include cardiovascular events (increased blood pressure and heart rate), psychiatric symptoms such as psychosis or mania, peripheral vasculopathy (Raynaud's phenomenon), and growth suppression in children with long-term use. Contact your doctor immediately if you experience chest pain, shortness of breath, or unusual behavioral changes.
If you're unable to find Dexmethylphenidate XR in stock, consider discussing these alternatives with your doctor:
Dexmethylphenidate XR has several important drug interactions to be aware of:
Always inform your doctor and pharmacist of all medications you are taking before starting Dexmethylphenidate XR.
Dexmethylphenidate XR remains an effective and widely prescribed treatment for ADHD, but the ongoing stimulant shortage continues to make it challenging to find in stock in 2026. With a findability score of just 40 out of 100, patients should plan ahead and explore multiple pharmacy options when filling prescriptions.
Generic versions offer significant savings at $40 to $150 per month compared to $250 to $490 for brand-name Focalin XR. Novartis also offers a savings card and patient assistance program for eligible patients. If you're struggling to locate Dexmethylphenidate XR, use Medfinder to search pharmacies near you that currently have it in stock, and consider asking your doctor about alternative ADHD medications as a backup plan.
%2C%20Color%3DOriginal.png)
